CytomX Therapeutics, Inc.
Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof

Abstract:

The invention relates generally to antibodies that specifically bind programmed cell death protein 1 (PD-1), activatable antibodies that specifically bind to PD-1 and methods of making and using these anti-PD-1 antibodies and anti-PD-1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.